Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition containing amino amantadine mononitrate compounds and used for eyes as well as preparation and application of composition

An ophthalmic composition and amantadine technology, applied in the field of medicine, can solve the problems of increasing the possibility of drug toxicity, difficult to achieve effective concentration, poor clinical compliance, etc., and achieve long release duration, lasting effect, and use compliance good effect

Inactive Publication Date: 2017-12-01
FOSHAN MAGPIE PHARM CO LTD
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The main disadvantages are: first, long-term medication is required for glaucoma treatment, and the clinical compliance of injection administration is poor; second, the drug is distributed throughout the body after injection or oral administration, and the drug concentration at the target site is low, making it difficult to reach the effective concentration. And due to the systemic exposure of the drug, the possibility of drug toxicity is increased

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition containing amino amantadine mononitrate compounds and used for eyes as well as preparation and application of composition
  • Composition containing amino amantadine mononitrate compounds and used for eyes as well as preparation and application of composition
  • Composition containing amino amantadine mononitrate compounds and used for eyes as well as preparation and application of composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] 1. Production of New Zealand Rabbit Transient Glaucoma Model

[0036] New Zealand rabbits with a body weight ranging from 1.5 to 2 kg were selected as model animals to make a high intraocular pressure model. The New Zealand rabbits were kept in a clean animal room for 3 days, and the experiment started after reaching the required body weight range. First, use pentobarbital sodium (3%, 1ml / kg) to anesthetize until there is no blink reflex; then, use compound tropicamide eye drops to dilate the pupils, and oxybucaine hydrochloride eye drops for local anesthesia. Boom eye drops to prevent dry eyes, levofloxacin eye drops to reduce inflammation, and iodine to disinfect around the eyes; inject 0.1ml of 5% hypertonic saline into the vitreous, using a 33G needle, and the injection site is the limbus After 3.5-4mm, the injection depth is 5-7mm; after withdrawing the needle. Tonolab intraocular pressure gauge was used to measure the change of intraocular pressure 1 min after t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicines, in particular to composition containing amino amantadine mononitrate compounds and used for eyes as well as a preparation and an application of the composition. The composition containing amino amantadine mononitrate compounds and used for the eyes is provided, wherein the mass volume ratio of the amino amantadine mononitrate compounds in the composition used for the eyes is 0.001%-5%. The invention further provides an application of the preparation used for the eyes in preparation of a drug for preventing and treating glaucoma, increased intraocular pressure or eye diseases with ganglia retinae cell injury. The provided preparation for the eyes has the advantage of facilitating use of patients suffering from eye diseases, allows the patients to have better compliance during use and is suitable for being taken for a long time by the patients suffering from glaucoma and high intraocular pressure. Besides, the concentration of the drug containing the amino amantadine mononitrate compounds at the target parts is increased through local drug administration, the drug takes effect rapidly and has high effective concentration, and the gain to risk ratio of the patients is high.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to an ophthalmic composition of aminoamantadine mononitrate compound and its preparation and application. Background technique [0002] Glaucoma (Glaucoma) refers to the eye disease when the intraocular pressure exceeds the limit that the intraocular tissue, especially the optic nerve, causes optic disc depression, optic nerve atrophy and visual field defect. If it is not treated in time, the visual field can be completely lost or even blind. The second leading cause of blindness in the world, approximately 8.4 million people worldwide are blinded by glaucoma. Normal people's intraocular pressure ranges from 10 to 21mmHg (Schitz intraocular pressure gauge). If the intraocular pressure exceeds 24mmHg, it is a pathological state. High intraocular pressure can lead to permanent and irreversible damage to visual function. High intraocular pressure continues The longer the time, the mo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/13A61P27/06A61P27/02A61K9/06A61K9/08
CPCA61K9/0002A61K9/0048A61K9/06A61K9/08A61K31/13
Inventor 王玉强孙业伟张在军张高小于沛易鹏
Owner FOSHAN MAGPIE PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com